Actient Pharmaceuticals is a specialty therapeutics company focused on urology as well as other select specialty areas.
Actient was founded in 2009, with the goal of developing, acquiring and marketing specialty products that significantly improve patient outcomes.
In July 2010, Actient entered into a license and purchase agreement with UCB Pharma, based in Brussels, Belgium. This commercial agreement brought six pharmaceutical products into the Actient portfolio including the urology product, Edex® (alprostadil for injection). It has since expanded to include urology devices to treat erectile dysfunction (ED) by acquiring Timm Medical Inc.
And in April, 2011, Actient further broadened its urology portfolio by acquiring the U.S. rights to Striant® (testosterone buccal system) from Columbia Laboratories, Inc.
You can view Actient’s product portfolio here.
About GTCR
Actient Pharmaceuticals is funded by GTCR Golder Rauner, LLC, a leader in the private equity industry for more than 25 years. GTCR pioneered the investment strategy of forging partnerships with industry executives, who are experienced in operations, to manage and successfully build acquired companies. GTCR manages more than $8 billion in equity with a strategic focus on high-growth industries and significant investment experience in both specialty branded and generic pharmaceutical companies.
GTCR’s unique investment strategy has proven successful with other healthcare companies such as:
- APS Healthcare, Inc.
- Capella Healthcare, Inc.
- Graceway Pharmaceuticals, Inc.
- Ovation Pharmaceuticals, Inc.
For more information, please contact us.